logo
Ellenbarrie Industrial Gases IPO GMP rises to 6%; issue subscribed 9% on Day 2

Ellenbarrie Industrial Gases IPO GMP rises to 6%; issue subscribed 9% on Day 2

Time of India5 hours ago

The initial public offering (IPO) of Ellenbarrie Industrial Gases was subscribed 9% so far on the second day of bidding on Wednesday, up from 8% on Day 1.
As of 10:03 am, the IPO had received bids for 12,95,222 shares, or 9% of the total issue size of 1,51,08,983 shares. The retail investor portion was subscribed 15%, while the non-institutional investor (NII) category saw a 9% subscription. The qualified institutional buyer (QIB) segment was yet to be subscribed.
In the grey market, Ellenbarrie Industrial Gases shares were trading at a premium of Rs 25–26, up from Rs 7–9 on Day 1. This means the GMP has risen to around 6% from 1.75%.
Also Read:
These 10 penny stocks under Rs 10 surged 200-570% in last 1 year. Do you own any?
IPO details
Live Events
The public issue includes a fresh equity issuance worth Rs 400 crore along with an offer for sale (OFS) of 1.13 crore shares. Ahead of the launch, the company successfully secured Rs 256 crore from anchor investors.
The price band has been set at Rs 380 to Rs 400 per share, with a minimum application size of 37 shares. The shares are proposed to be listed on both the NSE and BSE.
The IPO proceeds will be utilised to repay debt amounting to Rs 210 crore, establish a 220 TPD air separation unit at the company's Uluberia-II plant at a cost of Rs 104.5 crore, and meet general corporate requirements. Eastern India Gases Ltd (EIGL) also plans to commission three new plants by FY26, aiming to increase its total installed capacity from 3,861 TPD to 4,551 TPD.
Also Read:
Jio Financial surges over 50% from March lows: Will the momentum sustain?
About Ellenbarrie Industrial Gases
Founded over five decades ago, EIGL manufactures and supplies a wide range of industrial gases such as oxygen, nitrogen, argon, and acetylene, along with speciality gases, medical gases, and cryogenic storage systems. It operates nine facilities across East, South, and Central India, servicing industries like steel, pharmaceuticals, defence, healthcare, and railways.
The company reported a 26.7% PAT margin in FY25 with net profit of Rs 83.3 crore, EBITDA margin of 35.8%, and return on equity of 16.9%. At the upper end of the price band, the stock is valued at 62.9x FY25 earnings.
Also Read:
Coforge among 10 high-conviction stock ideas that can rally up to 52%
Should you subscribe to the Ellenbarrie Industrial Gases IPO?
SBI Securities has rated the IPO as Subscribe, citing EIGL's improving margin profile, strong client base, strategic capacity expansion, and attractive valuation compared to listed peers like
Linde India
.
(
Disclaimer
: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of Economic Times)

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Samsung Galaxy Z Fold 7, Galaxy Z Flip 7 pre-reservation begin in India: Here's how you can pre-reserve the upcoming foldable smartphones
Samsung Galaxy Z Fold 7, Galaxy Z Flip 7 pre-reservation begin in India: Here's how you can pre-reserve the upcoming foldable smartphones

Time of India

time27 minutes ago

  • Time of India

Samsung Galaxy Z Fold 7, Galaxy Z Flip 7 pre-reservation begin in India: Here's how you can pre-reserve the upcoming foldable smartphones

Samsung recently announced its Galaxy Unpacked 2025 event will take place on July 9 in Brooklyn, New York, at 10:00 AM ET (7:30 PM IST), where the tech giant is expected to unveil its next-generation Galaxy Z Fold 7 and Galaxy Z Flip 7 smartphones featuring a revolutionary AI-powered interface. The event will be livestreamed on Samsung's website and YouTube channel. The company has now started pre-reservation for its upcoming flagship foldable smartphone series in India. Samsung Galaxy Z Fold 7, Galaxy Z Flip 7 pre-reservation starts in India Samsung has now started pre-reservation for the upcoming Galaxy Z Fold 7 and Galaxy Z Flip 7 in India. The company has announced that customers can pre-reserve the upcoming foldable smartphones by paying a token amount of Rs 2,000. The company has also revealed that the customers who will pre-reserve the smartphone will get benefit worth Rs 5,999 on the purchase. Along with this, the customers will also be eligible for early delivery. Customers can pre-reserve the devices by visiting Samsung Exclusive Stores , and leading retail outlets across India. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo What to expect at Samsung's Galaxy Unpacked July Expected product launches include the Galaxy Z Fold7, rumored to feature Samsung's largest foldable display yet at 8.2 inches, surpassing competitors. The Galaxy Z Flip7 will reportedly be powered by Samsung's newly introduced Exynos 2500 Deca-Core processor and come in jet black, blue shadow, and coral red variants. A more affordable Galaxy Z Flip 7 FE model is also anticipated. Beyond smartphones, Samsung is expected to expand its wearables portfolio with the Galaxy Watch 8 series, including standard, Classic, and Ultra 2025 models. The recently teased Galaxy Buds Core may also debut at the event. Additional announcements may include updates on Project Moohan, Samsung's collaboration with Google on extended reality headsets, and the company's rumored tri-fold smartphone development.

Lupin receives USFDA approval for generic Prucalopride tablets
Lupin receives USFDA approval for generic Prucalopride tablets

Business Standard

time28 minutes ago

  • Business Standard

Lupin receives USFDA approval for generic Prucalopride tablets

Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its abbreviated new drug application (ANDA) for Prucalopride tablets. The tablets are a generic equivalent of Motegrity Tablets, developed by Takeda Pharmaceuticals U.S.A., Inc., and are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Lupin stated that the approved product is bioequivalent to Motegrity and will be manufactured at the companys facility in Goa, India. According to IQVIA MAT data for April 2025, Prucalopride Tablets (Reference Listed Drug: Motegrity) had estimated annual sales of approximately $184 million in the United States. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.07% to Rs 1,932.10 on the BSE.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store